BioNTech (BNTX) director reports 1,927 shares held via beebusy Capital

Rhea-AI Filing Summary

BioNTech SE director Ulrich Wandschneider filed an initial statement of beneficial ownership. The filing reports indirect beneficial ownership of 1,927 ordinary shares.

The shares are held by beebusy Capital GmbH, where Wandschneider is the sole shareholder and may be deemed to beneficially own the shares. The filing does not report any recent share purchases or sales, only this existing position.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wandschneider Ulrich

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ GERMANY D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	1,927	I	See Footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares are held by beebusy Capital GmbH. The Reporting Person is the sole shareholder of beebusy Capital GmbH and may be deemed to beneficially own the ordinary shares held by beebusy Capital GmbH.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does BioNTech (BNTX) disclose in Ulrich Wandschneider’s Form 3?

BioNTech reports Ulrich Wandschneider’s initial beneficial ownership as a director. The Form 3 shows he indirectly holds 1,927 ordinary shares through beebusy Capital GmbH, establishing a baseline of his equity position without detailing any new transactions.

How many BioNTech (BNTX) shares does Ulrich Wandschneider report on Form 3?

Ulrich Wandschneider reports indirect beneficial ownership of 1,927 BioNTech ordinary shares. This amount reflects his position as of the filing, giving investors a clear starting point for his equity stake as a director associated with beebusy Capital GmbH.

Are Ulrich Wandschneider’s BioNTech (BNTX) shares held directly or indirectly?

The Form 3 shows Wandschneider’s BioNTech shares are held indirectly. The 1,927 ordinary shares are owned by beebusy Capital GmbH, and he is its sole shareholder, so he may be deemed to beneficially own the shares through that entity.

Does Ulrich Wandschneider’s BioNTech (BNTX) Form 3 show any share purchases or sales?

No, the Form 3 does not list any purchases or sales. It records a holding entry only, with transaction summaries showing no buy or sell activity, simply establishing his existing beneficial ownership of 1,927 ordinary shares through beebusy Capital GmbH.

Who is beebusy Capital GmbH in relation to BioNTech (BNTX) director Ulrich Wandschneider?

beebusy Capital GmbH is the entity that holds the reported BioNTech ordinary shares. The filing states Wandschneider is the sole shareholder of beebusy Capital GmbH and may be deemed to beneficially own the 1,927 ordinary shares held by the company.